Bailard’s Zevra Therapeutics ZVRA Stock Holding History

Bailard’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$211K	Hold	14,700	–	–	﹤0.01%	727
2026 Q1	$137K	Buy	14,700 +1,800	+14%	+$16.2K	﹤0.01%	712
2025 Q4	$116K	Buy	+12,900	New	+$122K	﹤0.01%	735

Other funds holding ZVRA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bailard's ZVRA Position: Q2 2026 in Review

Bailard held its Zevra Therapeutics (ZVRA) position steady in Q2 2026 at 14,700 shares worth $211K. The position accounts for ﹤0.01% of the portfolio, ranked #727.

Bailard first reported a position in ZVRA in Q4 2025 and has held it in 3 quarters since. 158 funds tracked by Wall St. Rank hold ZVRA as of Q2 2026.

Bailard held 14,700 shares of Zevra Therapeutics worth $211K as of Q2 2026.
Bailard left its Zevra Therapeutics share count unchanged in Q2 2026.
Zevra Therapeutics made up ﹤0.01% of Bailard's portfolio in Q2 2026, its #727 holding.
Bailard first reported a position in Zevra Therapeutics in Q4 2025 and has held it in 3 quarters since.
158 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2026.

Based on Bailard's 13F filing for Q2 2026, filed 30 Jul 2026.